Niney percent of lupus patients want to reduce medical costs in the future.

The Blue Book of Systemic Lupus in China (hereinafter referred to as the Blue Book) was published on August 26th.
As an important part of the Blue Book, the research report analyzes the unfinished needs of SLE patients in China from many angles, such as the living status, health and social needs of patients with systemic lupus (System Lupus Erythematosus).
clinical science and academic parts, the Blue Book will better guide the diagnosis and treatment of SLE in China.
more than half of patients consider themselves to be in a serious condition, there is an urgent need to strengthen disease control SLE is a systemic autoimmune disease that affects multiple systems and organs throughout the body.
good in 15-45 years of age women of childbearing age, to repeated recurrence and remission as the main clinical characteristics, the disease can cause organ damage early, if not treated in time, will cause irreversible damage to the organs, and ultimately lead to the death of patients.
SLE is not curable at present, most patients face repeated recurrence of the disease, which brings heavy economic and psychological burden to patients, seriously affecting their quality of life.
In this study, just over 30 percent of patients said they were in good health or well, 54 percent said they were in a serious condition with one or more organs suffering from complications, and 76 percent said their current health state more or less affected their social activities.
"In the course of our research, we found that there are still many SLE patients in China who have lost their normal employment due to illness, and even have the opportunity to start a family and give birth to the next generation, and they are eager to return to society and live a normal life, " said Professor Su Wei, deputy director of Tsinghua University's Institute of Health Communication.
So we recommend multi-platform disease information dissemination activities and popular science work, can listen to the voice and needs of patients, help patients and the public to get more effective information, while awakening the community's concern for SLE patients, improve various social security systems, and effectively improve the quality of life of SLE patients.
" to improve the access to innovative drugs, is the key to break the SLE diagnosis and treatment dilemma in China in the past, China's SLE patients in a long-term state of lack of medical care, including glucosticoids, immunosuppressants, including traditional treatment options still face poor disease control and drug toxicity challenges: nearly 80% of SLE patients long-term use of hormones, 60% of patients continue to active or repeated disease recurrence.
, the most widely used glucoticoid in current SLE patients, can quickly control disease activity in the short term, but there is currently a long-term use of hormones.
survey showed that long-term use of hormones can lead to metabolic and electrolyte disorders (fattening, buffalo back, full moon face, etc.) (83%), osteoporosis (femur necrosis) and vertebral compression fractures (22%) and irreversible organ damage (19%).
while in disease control, patients with SLE were most in need of reducing the rate of recurrence (94 per cent), followed by reduced hormone use (90 per cent) and rapid disease control activity (88 per cent). Professor Li Mengtao, Deputy Director of Rheumatology Immunology At Beijing Concord Hospital,
The therapeutic concept of rheummatology immunology has been significantly improved and we will minimize the long-term or high-dose use of hormones."
advances in medicine have also led to safer and more effective hormone replacement drugs, including innovative biologics, that can help patients better manage their disease.
" In addition, the health and financial situation of SLE patients is under enormous pressure due to poor disease control due to the limitations of routine treatment, repeated relapses, and increased organ stress, such as lupus kidneys.
survey, 91 per cent of patients felt that the costs of current treatment were a burden on them;
Xiaofeng, director of rheumatology immunology at Beijing Concord Hospital, said: "The biggest challenge facing the treatment of SLE disease in China is the lack of medical care and medicine.
, many primary hospitals do not have corresponding departments, making it impossible for patients to be effectively managed and treated at the grass-roots level.
last year, the National Health and Wellness Commission issued a paper, decided to promote the development of rheummatoid immunology disciplines, the lack of medical treatment will be alleviated.
Professor Zeng Xiaofeng stressed: "SLE needs long-term standardized treatment, if the patient's early medication and delayed treatment leading to disability consequences, as well as related family and social burden, economic comparison, through the reasonable price after the negotiation of health insurance, the quality of drugs into health insurance, really improve the patient's prognostic, improve quality of life, reduce disability rate, is very cost-effective."
, it is equally urgent to accelerate dual access to innovative drugs in hospitals and health care.
Hu Ningning, vice president of the China Primary Health Care Foundation, said: "The China Primary Health Care Foundation has always pursued the goal of 'health for all', and the Blue Book project aims to raise society's attention to SLE patients so as to meet their most urgent and unfinished needs, fundamentally improve the fairness, access and effectiveness of health services."
" Reference 1. Chinese Rheumatology Association. Guidelines for diagnosis and treatment of systemic lupus erythematosus. China J Intern Med, 2010, 14 (5): 342-346. DOI: 10.3760/cma.j.issn.1007-7480.2010.05.0162. Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009;61:1152-8.3.Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual when the early disease course in a media inception cohort of patients with systemic lupus erythematosus . Lupus, 2010, 19 (8): 949-956. DOI: 10.1177/0961203310366572.Source:MedSci !-- Content Presentation Ends -- !-- To Determine If Login Ends.